Developing Best-in-Class Radiopharmaceuticals for Cancer Patients
Rx for Biotech
English - September 19, 2023 12:56 - 28 minutes - 25.9 MBBusiness Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: ASGCT Policy Summit Preview
Next Episode: The IRA 1-year Anniversary Episode: What Lies Ahead?
Our guests for this podcast episode are the co-founders of Ratio Therapeutics, CEO Jack Hoppin, PhD, and Chief Scientific Officer, John Babich, PhD.
Ratio Therapeutics's mission is to develop best-in-class radiopharmaceuticals for the treatment of cancers.